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Background: Tumor necrosis factor alpha (TNFα) is a key cytokine in both the pathogenesis 
of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) and the host defense against 
tuberculosis (TB). Consequently, anti-TNFα medications result in an increased risk of latent 
TB infection (LTBI) reactivation. Here, we sought to evaluate the factors affecting the results 
of QuantiFERON-TB Gold In-Tube (QFT-GIT) assay as a screening tool for LTBI.
Methods: We conducted an observational, retrospective study in patients with IBD and RA 
who underwent LTBI screening using QFT-GIT at UMass Memorial Medical Center between 
2008 and 2016 prior to initiation of anti-TNF medications.
Results: We included 107 and 89 patients with IBD and RA, respectively. We found that a 
higher proportion of IBD patients had indeterminate QFT-GIT result compared to RA patients. 
Furthermore, we found that the majority of patients with indeterminate results were tested during 
an acute flare of IBD (88%) and while taking corticosteroids. Of all patients receiving ≥20 mg 
equivalent prednisone dose (n=32), 63% resulted in indeterminate QFT-GIT, compared to only 
6% indeterminate testing in patients receiving <20 mg of equivalent prednisone dose (n=164, 
P<0.001). There was no correlation between indeterminate results and age, gender, disease 
duration, or distribution, or smoking status within each population.
Conclusion: We observed that high-dose corticosteroids may affect QFT-GIT outcomes leading 
to a high proportion of indeterminate results. We propose that IBD patients should be tested 
prior to initiation of corticosteroids to avoid equivocal results and prevent potential delays in 
initiation of anti-TNF medications.
Keywords: indeterminate QuantiFERON-TB Gold, latent TB infection, inflammatory bowel 
disease, rheumatoid arthritis, corticosteroids, IBD flare
Introduction
An estimated 2 billion people worldwide are affected by latent tuberculosis infection 
(LTBI).1,2 Many patients with LTBI never exhibit any signs of infection and remain 
asymptomatic for many years. However, LTBI reactivation remains a major cause of 
mortality and morbidity worldwide. Globally, 8.8 million new cases of active infections 
are diagnosed annually resulting in 1.8 million deaths.3 The incidence of both active and 
latent tuberculosis (TB) in the US is lower than global average.4 However, reactivation 
of LTBI in at-risk patients, particularly immunosuppressed patients, remains a concern.
Tumor necrosis factor alpha (TNFα) is a key cytokine in pathogenesis of various 
inflammatory conditions including inflammatory bowel disease (IBD)5 and rheuma-
toid arthritis (RA); therefore, blockade of the TNFα signaling pathway is very effec-
tive in the treatment of these diseases.6 Furthermore, TNFα is also a key cytokine in 
Correspondence: Shahrad Hakimian 
Department of Internal Medicine, UMass 
Memorial Medical Center, 55 Lake 
Avenue North, Worcester, MA 01655, 
USA 
Tel +1 310 968 5961 
Fax +1 508 856 3981 
Email Shahrad.hakimian@umassmemorial.
org
Journal name: Biologics: Targets and Therapy
Article Designation: ORIGINAL RESEARCH
Year: 2018
Volume: 12
Running head verso: Hakimian et al
Running head recto: QuantiFERON-TB Gold testing prior to biologics
DOI: http://dx.doi.org/10.2147/BTT.S150958
 
Bi
ol
og
ics
: T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
23
0.
51
 o
n 
17
-A
pr
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Biologics: Targets and Therapy 2018:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
62
Hakimian et al
the development and maintenance of the granuloma that 
compartmentalizes tuberculous bacilli and therefore plays 
a major role in protective host defense against Mycobacte-
rium tuberculosis (MTB).7 Consequently, TNFα inhibitors 
result in an increased risk of LTBI reactivation8 and have 
been implicated in several deaths.9,10 Therefore, screening 
for LTBI is the standard protocol prior to initiating anti-
TNF therapy.11 However, the best screening strategy in this 
population remains controversial.
The tuberculin skin test (TST) is the older method of 
screening for LTBI.12 TST is performed by injecting purified 
protein derivative (PPD) into the forearm and measuring the 
diameter of skin induration after 48–72 h.13 PPD is a spe-
cies nonspecific precipitate of MTB derivatives and relies 
on the ability of the immune system to form skin induration 
in response to the foreign antigen.14 Therefore, TST has low 
sensitivity and specificity, especially in the population of 
patients with inflammatory condition and patients previ-
ously vaccinated with Bacillus Calmette–Guérin (BCG).15 
Evidence indicates that patients with active IBD or RA may 
exhibit anergy in up to 80% of cases especially in the pres-
ence of corticosteroids resulting in false-negative results,16–18 
which lowers the sensitivity even further.
More recently, several companies have developed blood 
tests known as interferon-gamma release assays (IGRAs) 
as an alternative to TST in screening for LTBI.19–21 These 
assays employ the innate ability of T cells to release inter-
feron gamma in response to exposure to specific antigens. 
QuantiFERON-TB Gold In-Tube (QFT-GIT) assay is an 
IGRA that uses ELISA to quantify interferon-gamma release 
in vitro when patient’s whole blood is exposed to a cocktail of 
3 mycobacterial proteins (ESAT-6, CFP-10, and TB 7.7). This 
protein cocktail is more specific to MTB and does not cross-
react with prior BCG vaccination,22 increasing the specificity 
of the test. Additionally, QFT-GIT includes internal positive 
and negative controls to increase the sensitivity of the test. 
However, there are only a few reports23–25 that evaluate the 
utility of LTBI screening by QFT-GIT in a setting of active 
inflammation or steroid use. Here, we sought to evaluate 
the factors that affect the results of QFT-GIT when used 
specifically as a screening tool for LTBI prior to initiation 
of anti-TNF medications.
Methods
This observational, retrospective, single-center study 
included patients with IBD (Crohn’s disease or ulcerative 
colitis) and RA who underwent screening for LTBI using 
QFT-GIT at UMass Memorial Medical Center between 2008 
and 2016 prior to initiation of anti-TNF medications. Patients 
were identified through billing codes, and the diagnoses were 
verified by chart review of clinical data. Inclusion criteria 
included age >18 years, correct diagnosis of IBD and RA, 
and available QFT-GIT results. Our protocol was approved by 
the University of Massachusetts Medical School Institutional 
Review Board (IRB), application number H00010536. A 
waiver of consent was granted by the IRB as the data were 
retrospective and included older records that could not be 
reasonably tracked back to all individual patients, some of 
whom have moved or passed away since. Such inclusion of 
missing data would add selection bias and limit data inter-
pretation. Data extracted for analysis included demographics, 
disease phenotype, duration of disease, measures of disease 
activity, imaging, and endoscopic data. All data collection 
was conducted in accordance with state, local, and federal 
laws and as approved by the IRB.
IBD was defined by the presence of symptoms consistent 
with IBD in addition to objective inflammation as evidenced 
by elevated inflammatory markers (erythrocyte sedimentation 
rate [ESR], C-reactive protein [CRP], and fecal calprotec-
tin), computed tomography (CT) findings of inflammation 
consistent with IBD, and/or endoscopic findings consistent 
with IBD. RA diagnosis was based on American College of 
Rheumatology/European League Against Rheumatism Col-
laborative Initiative 2010 classification criteria.26 IBD and RA 
flare were defined by treating clinician’s determination. This 
determination was generally based on worsening of symp-
toms, elevation of inflammatory markers, new or worsening 
imaging or endoscopic evidence of inflammation. RA disease 
severity was assessed based on 2 commonly used previously 
validated scoring systems for RA: global assessment of RA 
and disease activity assessment (DAS 28). Corticosteroid 
dosing is presented in oral prednisone dose equivalents.
Patient’s blood samples were tested for LTBI using QFT-
GIT manufactured by QIAGEN NV (Venlo, the Netherlands), 
run by Quest Diagnostics Laboratory. In this technique, each 
patients’ blood sample was collected in 3 separate tubes. Qnil 
tube contained all test components but no TB antigen. This 
tube, therefore, serves as the negative control for the test and 
controls for background interferon-gamma release as mea-
sured by ELISA. Qmito tube contains mitogen, a mixture of 
components that should always result in interferon-gamma 
release regardless of prior to exposure to TB. This tube serves 
as the positive control for the test and assesses the ability of 
the immune cells in the blood sample to mount a response 
and produce interferon gamma in response to antigens. The 
third tube, TB-Ag, contains a cocktail of 3 mycobacterial 
 
Bi
ol
og
ics
: T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
18
9.
23
0.
51
 o
n 
17
-A
pr
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Biologics: Targets and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
63
QuantiFERON-TB Gold testing prior to biologics
proteins (ESAT-6, CFP-10, and TB 7.7) and should only result 
in interferon-gamma release in the case of prior exposure to 
MTB. Positive QFT-GIT result is defined per manufacturer 
as a TB-specific antigen response of >0.35 (IU/mL) with 
any mitogen control response. Negative result is defined 
as a TB antigen response of <0.35 (IU/mL) and a mitogen 
control response of >0.5 (IU/mL). Indeterminate response 
is defined as a TB antigen response of <0.35 (IU/mL) and a 
mitogen response of <0.5 (IU/mL). Statistical analysis was 
performed using Student’s t-test for continuous variables and 
chi-square test for binary variables.
Results
We identified 196 patients who underwent screening for LTBI 
using QFT-GIT prior to initiation of anti-TNF therapy. This 
included 107 patients with IBD (90 Crohn’s disease and 17 
ulcerative colitis) and 89 patients with RA. There were 61 
(57%) male and 46 (43%) female patients in the IBD group 
and 20 (22%) male and 69 (78%) female patients in the RA 
group. Baseline characteristics, disease duration, and distri-
bution are presented in Table 1.
In the IBD group, 82 patients (77%) had a negative QFT-
GIT result, 24 patients (22%) had an indeterminate result, and 
1 (1%) patient had a positive result. Of the IBD patients with 
indeterminate results, 21 of 24 patients (88%) were tested 
during an acute flare. We, therefore, further analyzed the QFT-
GIT results of all IBD patients tested during a flare and found 
that 21 of 43 (49%) patients had an indeterminate test result. 
Further stratification by steroid treatment within this group 
(IBD patients during a flare) showed that 18 of 24 (75%) 
patients on high-dose (≥20 mg) steroids had indeterminate 
test results as opposed to 3 of 19 (16%) who were on low dose 
(<20 mg) or no steroids. By contrast, in the RA cohort, 79 
patients (89%) had a negative  QFT-GIT result, 6 patients (7%) 
Table 1 Baseline characteristics of patients with IBD and RA included in the study
IBD patients n (%) RA patients n (%) P-value
Total 107 Total 89
Gender  Gender   
Male 61 (57) Male 20 (22) <0.001
Female 46 (43) Female 69 (77)  
Average agea 40.1±13.4 Average agea 55.8±10.7 <0.001
Age at diagnosisa 29.4±13.5 Age at diagnosisa 47.6±11.5 <0.001
Disease durationa 10.9±10.9 Disease durationa 8.2±5.3 0.02
Smoking 41 (38) Smoking 17 (19) <0.01
Ever hospitalized for IBD 70 (65) Family history of RA 9 (10)  
Surgical treatment for IBD 52 (49)  
Cancer history 3 (3)  
Corticosteroids use (in prednisone equivalent) Corticosteroids use (in prednisone equivalent)
No steroids 82 (77) No steroids 62 (70) 0.27
<20 mg 2 (2) <20 mg 18 (20) <0.001
20–35 mg 1 (1) 20–35 mg 9 (10) <0.001
≥40 mg 22 (20) ≥40 mg 0 (0) <0.001
IBD type  RA phenotype   
CD 90 (84) RF positive 34 (46)  
UC 17 (16) ACPA positive 23 (30  
Crohn’s disease distribution  RA disease activitya
Ileal 18 (20) DAS 28 score 3.58±1.46
Colonic 21 (24) Global assessment of RA 29.76±20.58
Ileocolonic 41 (46)
Isolated upper GI 8 (9)
Perianal disease 27 (25)
Small bowel involvement 62 (58)
Stricturing 31 (29)
Penetrating disease 42 (40)
UC type  
Proctitis (1) 1 (6)
Proctosigmoiditis (2) 3 (19)
Left-sided colitis (3) 3 (19)
Pancolitis (4) 9 (56)
Note: aData shown as mean ± standard deviation.
Abbreviations: ACPA, anti-citrullinated peptide antibodies; CD, Crohn’s disease; DAS, disease activity score; IBD, inflammatory bowel disease; RA, rheumatoid arthritis; 
RF, rheumatoid factor; UC, ulcerative colitis; GI, gastrointestinal.
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had indeterminate result, and 4 patients (5%) had positive 
results (Figure 1). There was no correlation between having 
an RA flare and indeterminate result in this group.
We next sought to evaluate the factors influencing the 
outcome of the QFT-GIT test. In our cohort, we found 
no correlation between an indeterminate QFT-GIT and 
age, gender, disease duration, or distribution, or smoking 
status within each population (IBD data shown in Table 
2). However, there was a strong correlation between an 
indeterminate QFT-GIT and active Crohn’s flare (peak ESR 
and CRP). Additionally, there was also a strong correlation 
between indeterminate QFT-GIT and corticosteroid use 
with a significantly higher rate of indeterminate results at 
an equivalent prednisone dose of ≥20 mg (Table 2B). As 
expected, indeterminate result was observed with inad-
equate response to positive control in the test (mitogen) 
(Figure S1).
Discussion
LTBI screening remains the standard protocol before 
initiating anti-TNF therapy. However, there are currently 
no standard methods of LTBI screening in patients with 
chronic inflammatory conditions such as IBD and RA. 
An ideal screening strategy should include a detailed his-
tory of risk factors for LTBI, as well as laboratory testing 
based on those risk factors. However, the most accurate 
laboratory test, and the ideal timing of testing, remains to 
be determined.
We examined the role of QFT-GIT assay as a screening 
tool for LTBI before initiation of anti-TNF therapy in a setting 
of active inflammation and corticosteroid use. We found that 
a high proportion of IBD patients have indeterminate results 
Figure 1 QFT-GIT screening result for RA patients (n=89), all IBD patients (n=107), IBD patients tested during a flare (n=43), and IBD patients tested during a flare with 
steroids (n=24) and without steroids (n=19). 
Note: Chi-squared test: RA vs IBD (P=0.003), all IBD vs IBD during flare (P=0.002), and IBD flare on high-dose steroids vs low-dose or no steroids (P<0.001).
Abbreviations: IBD, inflammatory bowel disease; QFT-GIT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis; RA, rheumatoid arthritis.
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Table 2 Factors affecting indeterminate QFT-GIT test results in 
IBD patients (A) and influence of corticosteroids on QFT-GIT 
results in IBD patients (B)
(A)
QFT-GIT result in  
IBD patients
Negative Indeterminate P-value
IBD type
CD 70 (85) 19 (79) 0.47
UC 12 (15) 5 (21)
Gender
Male 46 (56) 14 (58) 0.85
Female 36 (44) 10 (42)  
Average age 40.4±12.1 37.9±15.2 0.33
Age at diagnosis 29.8±13.2 28.4±14.7 0.67
Disease duration 10.9±10.1 10.7±13.8 0.94
Peak ESR 38.5±29.7 54.6±33.7 0.03
Peak CRP 43.5±62.1 90.6±81.2 0.004
(B)
QFT-GIT result in all  
IBD patients
Negative/ 
positive
Indeterminate  
Steroids >20 mg 6 (24) 19 (76) <0.0001
Steroids <20 mg or no 
steroids
77 (94) 5 (6)  
Note: Data shown as n (%) or mean ± standard deviation. 
Abbreviations: CD, Crohn’s disease; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; IBD, inflammatory bowel disease; QFT-GIT, QuantiFERON-TB 
Gold In-Tube; TB, tuberculosis; RA, rheumatoid arthritis; UC, ulcerative colitis.
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during active flares. No similar correlation was found in the 
RA population, though our RA cohort were generally treated 
less frequently with steroids and generally at lower doses at 
the time of testing. Furthermore, we found that corticosteroid 
treatment at the time of testing may be responsible for a high 
proportion of these indeterminate results as observed in our 
IBD patients, with higher indeterminate rates associated 
with higher steroid doses. This result, we suspect, is due to 
a blunted interferon-gamma response to the positive control 
(mitogen) portion of the IGRA test.
The question of whether RA patients can be reliably tested 
for LTBI with QFT-GIT while on corticosteroids remains 
open. Further studies exploring the association with higher 
doses of steroids may answer this question more specifically. 
However, the results in the IBD cohort suggest that, when 
possible, a patient with RA should ideally be tested for LTBI 
off steroid therapy and prior to initiation of TNFα inhibitors 
to minimize the chance of indeterminate result.
Despite our findings regarding high rates of indeterminate 
IGRA results, IGRAs such as QFT-GIT continue to serve 
as a useful tool for LTBI screening in the IBD population. 
IGRAs have previously been shown to have better sensitivity 
and specificity than TSTs in the general population.19 Other 
studies suggest that IGRAs may also be more sensitive than 
TSTs particularly in the IBD population during acute flares. 
The inclusion of a positive control distinguishes IGRAs 
from more traditional testing with TSTs. The TST has only 
a single readout, the appearance of a wheal, and does not 
have a positive control equivalent to the IGRA “mitogen” 
tube to determine whether the immune system is capable of 
mounting a response. Thus, the TST provides no method to 
readily distinguish between true- and false-negative results. 
This can markedly decrease the sensitivity of the test in the 
setting of an acute flare or corticosteroid treatment. Indeed, 
studies have reported high rates of anergy with TST in the 
setting of IBD and RA flares.16,17
By contrast, IGRAs such as QFT-GIT assay do have addi-
tional positive and negative controls (mitogen and nil antigen, 
respectively) to serve as internal quality controls for the test, 
thereby decreasing the false-positive and false-negative rates 
and increasing the sensitivity and specificity of the test, espe-
cially in a setting of corticosteroids when the sensitivity of the 
test might otherwise be compromised. Indeed, indeterminate 
QFT-GIT results were found to be more common among 
patients with negative TST results in an inpatient hospital 
population, many of whom were on immunosuppressive 
medications.27 IGRAs such as QFT-GIT are often chosen over 
TSTs when possible in the IBD population on corticosteroids 
when the corticosteroids cannot be practically weaned off 
before LTBI screening prior to initiation of anti-TNF therapy.
Our findings raise the question of how one might deal 
with indeterminate results. In these situations, one has to 
resort to clinical judgment based on patients’ TB risk fac-
tors and likelihood of disease. In our experience, some even 
suggest empirically treating high-risk patients for LTBI until 
more definite testing can be obtained off corticosteroids by 
repeat testing. However, one must balance the risk of LTBI 
reactivation in such patients with the risk of complications 
from treatment in a potentially uninfected individual. LTBI 
treatment is not a zero-risk proposition, and the risks of rash, 
liver toxicity, and drug–drug interactions remain a concern. 
The indeterminate results pose significant management 
questions.
Our study has certain limitations. First, it is a retrospective 
study that could not control for age differences in IBD and RA 
populations or doses of corticosteroids in each group. In this 
study, we have observed a lower rate of indeterminate results 
in the RA compared to IBD population. However, caution 
should be advised as patients in the RA group tend to have 
lower rates of corticosteroids treatment and are on lower doses 
of prednisone equivalents. Therefore, the difference seen here 
may not necessarily be specific to the disease process but rather 
the effect of corticosteroids. However, larger randomized con-
trolled trials controlling for age, gender, and steroid dose may 
elucidate other differences. Selection bias is also possible due 
to the retrospective nature of the study and ICD code-based 
ascertainment of diagnosis which may unintentionally exclude 
certain patients with RA and IBD. Future studies may evaluate 
whether the inflammatory process in IBD itself can interfere 
with QFT-GIT results in the absence of corticosteroids.
The consideration of instituting anti-TNF treatment, 
particularly in patients with IBD in the throes of an acute 
flare, often requires urgent decision-making. Such clinical 
scenarios can include the emergent consideration of anti-
TNF therapy to treat steroid-refractory disease and possibly 
avoid the need for surgical intervention. An indeterminate 
QFT-GIT result can delay induction with an anti-TNF medi-
cation while attempting to determine an appropriate response 
to the indeterminate result and the best treatment approach 
to possible LTBI. With our results indicating an association 
between steroid use and indeterminate QFT-GIT results, we 
suggest testing with QFT-GIT prior to initiation of, or even 
before the consideration of, steroids to prevent delays in 
initiation of anti-TNF therapy if needed later in a patient’s 
course. Accordingly, many experts advocate TB testing at 
an initial encounter (or at initial diagnosis) of IBD to avoid 
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any urgent scenario of delay in anti-TNF induction due to 
an indeterminate LTBI test.
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QuantiFERON-TB Gold testing prior to biologics
Supplementary material
Figure S1 Comparison of QFT-GIT interferon-gamma release response (IU/mL) in patients with indeterminate, negative, and positive test results (n=24, 82, and 1).
Notes: As expected, there is no interferon-gamma release in Qnil tube in any of the groups. Qnil tube contains no TB antigens and serves as negative control for the test. 
On the other hand, as expected, there is strong response to Q-mito antigen in patients with the negative and positive test results; however, this response is blunted in the 
group with indeterminate test results. Q-mito tube serves as the positive control for the test and should always result in interferon-gamma release in case of a functioning 
immune system However, in the case of patients with indeterminate results, there is little to no interferon-gamma release to this antigen indicating dysfunctional immune cells 
(possibly related to steroids) that may not be able to release interferon gamma in response to other antigens including TB-specific antigens. TB-Ag tube contains a cocktail 
of 3 mycobacterial proteins (ESAT-6, CFP-10, and TB 7.7) and should only react if there is prior exposure to Mycobacterium tuberculosis.
Abbreviations: IGRA, immunoglobulin- release assay; QFT-GIT, QuantiFERON-TB Gold In-Tube; TB, tuberculosis.
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